Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Mathijssen, RHJ; van Alphen, RJ; Verweij, J; Loos, WJ; Nooter, K; Stoter, G; Sparreboom, A
   Clinical pharmacokinetics and metabolism of irinotecan (CPT-11)
   CLINICAL CANCER RESEARCH
   
   R.H.J. Mathijssen et al., "Clinical pharmacokinetics and metabolism of irinotecan (CPT-11)", CLIN CANC R, 7(8), 2001, pp. 2182-2194
2. Laurie, SA; Pfister, DG; Kris, MG; Tong, WP; Chronowski, G; Pisters, KWM; Heelan, RT; Sirotnak, FM
   Phase I and pharmacological study of two schedules of the antifolate edatrexate in combination with cisplatin
   CLINICAL CANCER RESEARCH
   
   S.A. Laurie et al., "Phase I and pharmacological study of two schedules of the antifolate edatrexate in combination with cisplatin", CLIN CANC R, 7(3), 2001, pp. 501-509
3. Smorenburg, CH; Sparreboom, A; Bontenbal, M; Verweij, J
   Combination chemotherapy of the taxanes and antimetabolites: its use and limitations
   EUROPEAN JOURNAL OF CANCER
   
   C.H. Smorenburg et al., "Combination chemotherapy of the taxanes and antimetabolites: its use and limitations", EUR J CANC, 37(18), 2001, pp. 2310-2323
4. Schilder, RJ; Gallo, JM; Millenson, MM; Bookman, MA; Weiner, LM; Rogatko, A; Rogers, B; Padavic-Shallers, K; Boente, M; Rosenblum, N; Adams, AL; Ciccotto, S; Ozols, RF
   Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, andtopotecan with peripheral-blood stem-cell support as front-line therapy
   JOURNAL OF CLINICAL ONCOLOGY
   
   R.J. Schilder et al., "Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, andtopotecan with peripheral-blood stem-cell support as front-line therapy", J CL ONCOL, 19(4), 2001, pp. 1183-1194
5. de Jongh, FE; Verweij, J; Loos, WJ; de Wit, R; de Jonge, MJA; Planting, AST; Nooter, K; Stoter, G; Sparreboom, A
   Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure
   JOURNAL OF CLINICAL ONCOLOGY
   
   F.E. de Jongh et al., "Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure", J CL ONCOL, 19(17), 2001, pp. 3733-3739
6. Hartung, G
   New developments in chemotherapy of gastrointestinal carcinomas
   ONKOLOGIE
   
   G. Hartung, "New developments in chemotherapy of gastrointestinal carcinomas", ONKOLOGIE, 24, 2001, pp. 10-15
7. Heath, EI; O'Reilly, S; Humphrey, R; Sundaresan, P; Donehower, RC; Sartorius, S; Kennedy, MJ; Armstrong, DK; Carducci, MA; Sorensen, JM; Kumor, K; Kennedy, S; Grochow, LB
   Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors
   CANCER CHEMOTHERAPY AND PHARMACOLOGY
   
   E.I. Heath et al., "Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors", CANC CHEMOT, 48(4), 2001, pp. 269-274
8. Seymour, L; Eisenhauer, E
   A review of dose-limiting events in phase I trials: antimetabolites show unpredictable relationships between dose and toxicity
   CANCER CHEMOTHERAPY AND PHARMACOLOGY
   
   L. Seymour e E. Eisenhauer, "A review of dose-limiting events in phase I trials: antimetabolites show unpredictable relationships between dose and toxicity", CANC CHEMOT, 47(1), 2001, pp. 2-10
9. Cunningham, D; Coleman, R
   New options for outpatient chemotherapy - the role of oral fluoropyrimidines
   CANCER TREATMENT REVIEWS
   
   D. Cunningham e R. Coleman, "New options for outpatient chemotherapy - the role of oral fluoropyrimidines", CANC TR REV, 27(4), 2001, pp. 211-220
10. Margolin, K; Longmate, J; Synold, TW; Gandara, DR; Weber, J; Gonzalez, R; Johansen, MJ; Newman, R; Baratta, T; Doroshow, JH
    Dolastatin-10 in metastatic melanoma: A phase II and pharmokinetic trial of the california cancer consortium
    INVESTIGATIONAL NEW DRUGS
    
    K. Margolin et al., "Dolastatin-10 in metastatic melanoma: A phase II and pharmokinetic trial of the california cancer consortium", INV NEW DR, 19(4), 2001, pp. 335-340
11. Vigano, L; Locatelli, A; Grasselli, G; Gianni, L
    Drug interactions of paclitaxel and docetaxel and their relevance for the design of combination therapy
    INVESTIGATIONAL NEW DRUGS
    
    L. Vigano et al., "Drug interactions of paclitaxel and docetaxel and their relevance for the design of combination therapy", INV NEW DR, 19(2), 2001, pp. 179-196
12. Shah, MA; Schwartz, GK
    The relevance of drug sequence in combination chemotherapy
    DRUG RESISTANCE UPDATES
    
    M.A. Shah e G.K. Schwartz, "The relevance of drug sequence in combination chemotherapy", DRUG RESIST, 3(6), 2000, pp. 335-356
13. Enzinger, PC; Ilson, DH
    Irinotecan in esophageal cancer
    ONCOLOGY-NEW YORK
    
    P.C. Enzinger e D.H. Ilson, "Irinotecan in esophageal cancer", ONCOLOGY-NY, 14(12), 2000, pp. 26-30
14. Dutcher, JP; Novik, Y; O'Boyle, K; Marcoullis, G; Secco, C; Wiernik, PH
    20th-century advances in drug therapy in oncology - Part II
    JOURNAL OF CLINICAL PHARMACOLOGY
    
    J.P. Dutcher et al., "20th-century advances in drug therapy in oncology - Part II", J CLIN PHAR, 40(10), 2000, pp. 1079-1092
15. Markman, M; Blessing, JA; Alvarez, RD; Hanjani, P; Waggoner, S; Hall, K
    Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study
    GYNECOLOGIC ONCOLOGY
    
    M. Markman et al., "Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study", GYNECOL ONC, 77(1), 2000, pp. 112-115
16. Ford, HER; Cunningham, D; Ross, PJ; Rao, S; Aherne, GW; Benepal, TS; Price, T; Massey, A; Vernillet, L; Gruia, G
    Phase I study of irinotecan and raltitrexed in patients with advanced gastrointestinal tract adenocarcinoma
    BRITISH JOURNAL OF CANCER
    
    H.E.R. Ford et al., "Phase I study of irinotecan and raltitrexed in patients with advanced gastrointestinal tract adenocarcinoma", BR J CANC, 83(2), 2000, pp. 146-152
17. Bleiberg, H
    CPT-11 in gastrointestinal cancer
    EUROPEAN JOURNAL OF CANCER
    
    H. Bleiberg, "CPT-11 in gastrointestinal cancer", EUR J CANC, 35(3), 1999, pp. 371-379
18. Twelves, C
    UFT plus calcium folinate/irinotecan in colorectal cancer
    ONCOLOGY-NEW YORK
    
    C. Twelves, "UFT plus calcium folinate/irinotecan in colorectal cancer", ONCOLOGY-NY, 13(7), 1999, pp. 51-54
19. DeVore, RF; Johnson, DH; Crawford, J; Garst, J; Dimery, IW; Eckardt, J; Eckhardt, SG; Elfring, GL; Schaaf, LJ; Hanover, CK; Miller, LL
    Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer
    JOURNAL OF CLINICAL ONCOLOGY
    
    R.F. DeVore et al., "Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer", J CL ONCOL, 17(9), 1999, pp. 2710-2720
20. Ducreux, M; Ychou, M; Seitz, JF; Bonnay, M; Bexon, A; Armand, JP; Mahjoubi, M; Mery-Mignard, D; Rougier, P
    Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): A clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer
    JOURNAL OF CLINICAL ONCOLOGY
    
    M. Ducreux et al., "Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): A clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer", J CL ONCOL, 17(9), 1999, pp. 2901-2908
21. Herben, VMM; Panday, VRN; Richel, DJ; Schellens, JHM; van der Vange, N; Rosing, H; Beusenberg, FD; Hearn, S; Doyle, E; Beijnen, JH; Huinink, WWT
    Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer
    JOURNAL OF CLINICAL ONCOLOGY
    
    V.M.M. Herben et al., "Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer", J CL ONCOL, 17(3), 1999, pp. 747-755
22. Gelderblom, HAJ; de Jonge, MJA; Sparreboom, A; Verweij, J
    Oral topoisomerase 1 inhibitors in adult patients: Present and future
    INVESTIGATIONAL NEW DRUGS
    
    H.A.J. Gelderblom et al., "Oral topoisomerase 1 inhibitors in adult patients: Present and future", INV NEW DR, 17(4), 1999, pp. 401-415
23. Kollmannsberger, C; Mross, K; Jakob, A; Kanz, L; Bokemeyer, C
    Topotecan - A novel topoisomerase I inhibitor: Pharmacology and clinical experience
    ONCOLOGY
    
    C. Kollmannsberger et al., "Topotecan - A novel topoisomerase I inhibitor: Pharmacology and clinical experience", ONCOL-BASEL, 56(1), 1999, pp. 1-12
24. Partyka, S; Dumas, P; Ajani, J
    Combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with locoregional and metastatic gastric adenocarcinoma
    CANCER
    
    S. Partyka et al., "Combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with locoregional and metastatic gastric adenocarcinoma", CANCER, 85(11), 1999, pp. 2336-2339
25. Nakano, T; Chahinian, AP; Shinjo, M; Togawa, N; Tonomura, A; Miyake, M; Ninomiya, K; Yamamoto, T; Higashino, K
    Cisplatin in combination with irinotecan in the treatment of patients withmalignant pleural mesothelioma - A pilot phase II clinical trial and pharmacokinetic profile
    CANCER
    
    T. Nakano et al., "Cisplatin in combination with irinotecan in the treatment of patients withmalignant pleural mesothelioma - A pilot phase II clinical trial and pharmacokinetic profile", CANCER, 85(11), 1999, pp. 2375-2384
26. Cersosimo, RJ
    Irinotecan: A new antineoplastic agent for the management of colorectal cancer
    ANNALS OF PHARMACOTHERAPY
    
    R.J. Cersosimo, "Irinotecan: A new antineoplastic agent for the management of colorectal cancer", ANN PHARMAC, 32(12), 1998, pp. 1324-1333
27. HERBEN VMM; HUININK WWT; SCHELLENS JHM; BEIJNEN JH
    CLINICAL PHARMACOKINETICS OF CAMPTOTHECIN TOPOISOMERASE-I INHIBITORS
    Pharmacy world & science
    
    V.M.M. Herben et al., "CLINICAL PHARMACOKINETICS OF CAMPTOTHECIN TOPOISOMERASE-I INHIBITORS", Pharmacy world & science, 20(4), 1998, pp. 161-172
28. ENZINGER PC; ILSON DH; SALTZ LB; OREILLY EM; KELSEN DP
    IRINOTECAN AND CISPLATIN IN UPPER GASTROINTESTINAL MALIGNANCIES
    Oncology
    
    P.C. Enzinger et al., "IRINOTECAN AND CISPLATIN IN UPPER GASTROINTESTINAL MALIGNANCIES", Oncology, 12(8), 1998, pp. 110-113
29. LILENBAUM RC; MILLER AA; BATIST G; BERNARD S; HOLLIS DR; ROSNER GL; EGORIN MJ; SCHILSKY RL; RATAIN MJ
    PHASE-I AND PHARMACOLOGICAL STUDY OF CONTINUOUS-INFUSION TOPOTECAN INCOMBINATION WITH CISPLATIN IN PATIENTS WITH ADVANCED CANCER - A CANCER AND LEUKEMIA GROUP-B STUDY
    Journal of clinical oncology
    
    R.C. Lilenbaum et al., "PHASE-I AND PHARMACOLOGICAL STUDY OF CONTINUOUS-INFUSION TOPOTECAN INCOMBINATION WITH CISPLATIN IN PATIENTS WITH ADVANCED CANCER - A CANCER AND LEUKEMIA GROUP-B STUDY", Journal of clinical oncology, 16(10), 1998, pp. 3302-3309
30. DEJONGE MJA; SPARREBOOM A; VERWEIJ J
    THE DEVELOPMENT OF COMBINATION THERAPY INVOLVING CAMPTOTHECINS - A REVIEW OF PRECLINICAL AND EARLY CLINICAL-STUDIES
    Cancer treatment reviews
    
    M.J.A. Dejonge et al., "THE DEVELOPMENT OF COMBINATION THERAPY INVOLVING CAMPTOTHECINS - A REVIEW OF PRECLINICAL AND EARLY CLINICAL-STUDIES", Cancer treatment reviews, 24(3), 1998, pp. 205-220
31. TAKIMOTO CH; WRIGHT J; ARBUCK SG
    CLINICAL-APPLICATIONS OF THE CAMPTOTHECINS
    Biochimica et biophysica acta, N. Gene structure and expression
    
    C.H. Takimoto et al., "CLINICAL-APPLICATIONS OF THE CAMPTOTHECINS", Biochimica et biophysica acta, N. Gene structure and expression, 1400(1-3), 1998, pp. 107-119
32. ARBUCK SG; TAKIMOTO CH
    AN OVERVIEW OF TOPOISOMERASE-I - TARGETING AGENTS
    Seminars in hematology
    
    S.G. Arbuck e C.H. Takimoto, "AN OVERVIEW OF TOPOISOMERASE-I - TARGETING AGENTS", Seminars in hematology, 35(3), 1998, pp. 3-12
33. PUNT CJA
    NEW DRUGS IN THE TREATMENT OF COLORECTAL-CARCINOMA
    Cancer
    
    C.J.A. Punt, "NEW DRUGS IN THE TREATMENT OF COLORECTAL-CARCINOMA", Cancer, 83(4), 1998, pp. 679-689
34. Chabot, GG; Robert, J; Lokiec, F; Canal, P
    Irinotecan pharmacokinetics
    BULLETIN DU CANCER
    
    G.G. Chabot et al., "Irinotecan pharmacokinetics", B CANCER, 1998, pp. 11-20
35. ROTHENBERG ML
    TOPOISOMERASE-I INHIBITORS - REVIEW AND UPDATE
    Annals of oncology
    
    M.L. Rothenberg, "TOPOISOMERASE-I INHIBITORS - REVIEW AND UPDATE", Annals of oncology, 8(9), 1997, pp. 837-855
36. ZHANG Z; INSERRA PF; LIANG BL; ARDESTANI SK; ELLIOTT KK; MOLITOR M; WATSON RR
    MELATONIN, IMMUNE MODULATION AND AGING
    Autoimmunity
    
    Z. Zhang et al., "MELATONIN, IMMUNE MODULATION AND AGING", Autoimmunity, 26(1), 1997, pp. 43-53
37. PANZER A; VILJOEN M
    THE VALIDITY OF MELATONIN AS AN ONCOSTATIC AGENT
    Journal of pineal research
    
    A. Panzer e M. Viljoen, "THE VALIDITY OF MELATONIN AS AN ONCOSTATIC AGENT", Journal of pineal research, 22(4), 1997, pp. 184-202
38. MURREN JR; ANDERSON S; FEDELE J; PIZZORNO G; BELLIVEAU D; ZELTERMAN D; BURTNESS BA; TOCINO I; FLYNN SD; BEIDLER D; CHENG YC
    DOSE-ESCALATION AND PHARMACODYNAMIC STUDY OF TOPOTECAN IN COMBINATIONWITH CYCLOPHOSPHAMIDE IN PATIENTS WITH REFRACTORY CANCER
    Journal of clinical oncology
    
    J.R. Murren et al., "DOSE-ESCALATION AND PHARMACODYNAMIC STUDY OF TOPOTECAN IN COMBINATIONWITH CYCLOPHOSPHAMIDE IN PATIENTS WITH REFRACTORY CANCER", Journal of clinical oncology, 15(1), 1997, pp. 148-157
39. CHABOT GG
    CLINICAL PHARMACOKINETICS OF IRINOTECAN
    Clinical pharmacokinetics
    
    G.G. Chabot, "CLINICAL PHARMACOKINETICS OF IRINOTECAN", Clinical pharmacokinetics, 33(4), 1997, pp. 245-259
40. PANZER A
    MELATONIN IN OSTEOSARCOMA - AN EFFECTIVE DRUG
    Medical hypotheses
    
    A. Panzer, "MELATONIN IN OSTEOSARCOMA - AN EFFECTIVE DRUG", Medical hypotheses, 48(6), 1997, pp. 523-525
41. ROWINSKY EK; KAUFMANN SH
    TOPOTECAN IN COMBINATION CHEMOTHERAPY
    Seminars in oncology
    
    E.K. Rowinsky e S.H. Kaufmann, "TOPOTECAN IN COMBINATION CHEMOTHERAPY", Seminars in oncology, 24(6), 1997, pp. 11-26
42. SALTZ LB; KEMENY NE; TONG W; HARRISON J; BERKERY R; KELSEN DP
    9-AMINOCAMPTOTHECIN BY 72-HOUR CONTINUOUS INTRAVENOUS-INFUSION IS INACTIVE IN THE TREATMENT OF PATIENTS WITH 5-FLUOROURACIL-REFRACTORY COLORECTAL-CARCINOMA
    Cancer
    
    L.B. Saltz et al., "9-AMINOCAMPTOTHECIN BY 72-HOUR CONTINUOUS INTRAVENOUS-INFUSION IS INACTIVE IN THE TREATMENT OF PATIENTS WITH 5-FLUOROURACIL-REFRACTORY COLORECTAL-CARCINOMA", Cancer, 80(9), 1997, pp. 1727-1732
43. DENT SF; EISENHAUER EA
    PHASE-I TRIAL DESIGN - ARE NEW METHODOLOGIES BEING PUT INTO PRACTICE
    Annals of oncology
    
    S.F. Dent e E.A. Eisenhauer, "PHASE-I TRIAL DESIGN - ARE NEW METHODOLOGIES BEING PUT INTO PRACTICE", Annals of oncology, 7(6), 1996, pp. 561-566
44. VERWEIJ J
    NEW PROMISING ANTICANCER AGENTS IN DEVELOPMENT - WHAT COMES NEXT
    Cancer chemotherapy and pharmacology
    
    J. Verweij, "NEW PROMISING ANTICANCER AGENTS IN DEVELOPMENT - WHAT COMES NEXT", Cancer chemotherapy and pharmacology, 38, 1996, pp. 3-10
45. JONES CA; SHAW PJ; STEVENS MM
    USE OF GRANULOCYTE-COLONY-STIMULATING FACTOR TO REDUCE THE TOXICITY OF SUPER-VAC CHEMOTHERAPY IN ADVANCED SOLID TUMORS IN CHILDHOOD
    Medical and pediatric oncology
    
    C.A. Jones et al., "USE OF GRANULOCYTE-COLONY-STIMULATING FACTOR TO REDUCE THE TOXICITY OF SUPER-VAC CHEMOTHERAPY IN ADVANCED SOLID TUMORS IN CHILDHOOD", Medical and pediatric oncology, 25(2), 1995, pp. 84-89